Becton Dickinson Earnings: China, Noisy Margins Disappoint, but Long-Term Outlook Remains Upbeat
We are maintaining our fair value estimate for narrow-moat Becton, Dickinson following its fourth-quarter results. Shares are modestly undervalued.
Becton Dickinson & Co BDX
Bulls Say, Bears Say
Bulls
BD's surgery business delivered strong performance since the pandemic waned.
Bears
While BD passed on some price hikes, it isn't able to offset inflationary pressures entirely.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BDX is a good fit for your portfolio.
News
-
BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems
-
FDA Safety Communication Does Not Impact BD Syringes
-
BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency
-
BD Names Dr. Ronald Silverman as Chief Medical Officer
-
BD to Present at the 6th Annual Evercore ISI HealthCONx Conference
-
Becton, Dickinson and Co. Down Over 8%, on Pace for Largest Percent Decrease Since August 2020 — Data Talk
-
Becton Dickinson's Fiscal 2024 Outlook Falls Short of Wall Street View
-
Becton Dickinson Raises Quarterly Dividend by 4.4%
Trading Information
- Previous Close Price
- $233.63
- Day Range
- $232.44–234.86
- 52-Week Range
- $228.75–286.45
- Bid/Ask
- $233.02 / $233.23
- Market Cap
- $67.74 Bil
- Volume/Avg
- 1.0 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- 19.12
- Price/Sales
- 3.48
- Dividend Yield
- 1.56%
- Dividend Yield (Forward)
- 1.63%
- Total Yield
- 1.56%
Company Profile
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of estimated 2023 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Large Value
- Total Number of Employees
- 73,000
- Website
- https://www.bd.com
Competitors
Valuation
|
Metric
|
BDX
|
RHHBY
|
BAX
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.12 | 13.76 | 13.26 |
Price/Book Value | 2.63 | 7.77 | 2.24 |
Price/Sales | 3.48 | 3.52 | 1.22 |
Price/Cash Flow | 18.61 | 11.87 | 12.46 |
Price/Earnings
BDX
RHHBY
BAX
Financial Strength
|
Metric
|
BDX
|
RHHBY
|
BAX
|
|---|---|---|---|
Quick Ratio | 0.60 | 0.72 | 1.34 |
Current Ratio | 1.31 | 1.18 | 1.94 |
Interest Coverage | 4.57 | 17.42 | 1.16 |
Quick Ratio
BDX
RHHBY
BAX
Profitability
|
Metric
|
BDX
|
RHHBY
|
BAX
|
|---|---|---|---|
Return on Assets (Normalized) | 3.40% | 17.37% | 4.62% |
Return on Equity (Normalized) | 7.06% | 56.49% | 21.38% |
Return on Invested Capital (Normalized) | 5.15% | 27.41% | 7.35% |
Return on Assets
BDX
RHHBY
BAX
Medical Instruments & Supplies Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Kht | $109.0 Bil | |
ALC
| Alcon Inc | Gqvsz | $35.5 Bil | |
CLPBY
| Coloplast A/S ADR | Nbxd | $25.7 Bil | |
WST
| West Pharmaceutical Services Inc | Ffdy | $25.4 Bil | |
RMD
| ResMed Inc | Pzyyjmd | $23.7 Bil | |
BAX
| Baxter International Inc | Ldcbwng | $18.2 Bil | |
HOLX
| Hologic Inc | Rbnhzff | $16.6 Bil | |
COO
| The Cooper Companies Inc | Ckpsght | $16.6 Bil | |
TFX
| Teleflex Inc | Ncynb | $10.7 Bil |